✦ LIBER ✦

Therapy of hepatitis C: From empiricism to eradication

✍ Scribed by Jean-Michel Pawlotsky

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 536 KB
Volume: 43
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.21064

No coin nor oath required. For personal study only.

✦ Synopsis

The complications of chronic hepatitis C virus infection can be prevented by antiviral therapy. The initial choice of interferon alfa and, subsequently, ribavirin as potential treatments for chronic hepatitis C was empirical. Nevertheless, the combination of pegylated interferon alfa and ribavirin has become the standard treatment of chronic hepatitis C. Since the advent of interferon-based therapy, enormous progress has been made in understanding the mechanisms of treatment efficacy and failure, and in everyday patient management. The principal advances are: a better understanding of hepatitis C virus steady-state kinetics and the antiviral mechanisms of interferon and ribavirin; easier treatment decisions thanks to novel assays to assess liver disease severity and the virological characteristics of infection; a better use of virological tests to tailor therapy; a better management of adverse effects; a better understanding of virological treatment failure; and a better management of “special” populations, including patients with decompensated cirrhosis and end-stage liver disease, liver transplant recipients, hemodialysis patients and renal transplant recipients, human immunodeficiency virus-coinfected patients, intravenous drug users and patients on opiate replacement therapy, or virological non responders to previous therapies. Steady-state HCV kinetics offers several potential targets for new drugs. These targets should ideally be hit simultaneously in order to achieve viral eradication within a reasonable time frame. Future drugs for HCV infection will belong to four main categories, including new interferons, alternatives to ribavirin, specific HCV inhibitors, and immune modulators. New treatments and vaccines might make it possible to eradicate HCV in the future.

📜 SIMILAR VOLUMES

Therapy of hepatitis B — Viral suppressi

Therapy of hepatitis B — Viral suppression or eradication?

✍ Robert P. Perrillo 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB

## **The practicing clinician is currently faced with a number of treatment options for chronic hepatitis B. Beginning in 1998 with the licensing of lamivudine and subsequently adefovir, the treatment paradigm shifted from 4 to 6 months of conventional alfa interferon to a year of nucleoside analo

Introduction to therapy of hepatitis C

✍ Karen L. Lindsay 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 923 KB

Since the 1997 National Institutes of Health Consensus Development Conference on management of hepatitis C there have been several important advances that significantly impact its therapy; notably the availability of sensitive, specific, and standardized assays for identifying hepatitis C virus (HCV

Autoimmune hepatitis, from mechanisms to

Autoimmune hepatitis, from mechanisms to therapy

✍ Michael P. Manns; Arndt Vogel 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 336 KB

## **In 1950, Waldenström was the first to describe a chronic form of hepatitis in young women. Subsequently, the disease was found to be associated with other autoimmune syndromes and was later termed “lupoid hepatitis” because of the presence of antinuclear antibodies. In 1965, it became designa

Therapy of hepatitis C: Overview

✍ K L Lindsay 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

Based on the first decade of research on alpha interferon and improving hepatic histology. The discovery and characterization of the hepatitis C virus (HCV) led to reanalysis of in viral hepatitis, one can conclude that up to 40% of patients with compensated chronic hepatitis C and elevated alanine

Optimal therapy of hepatitis C

✍ Adrian M. Di Bisceglie; Jay H. Hoofnagle 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 745 KB

The highest response rates to antiviral therapy for the treatment of chronic hepatitis C have been achieved using the combination of peginterferon and ribavirin. Recently completed controlled trials have reported rates of sustained virological response (SVR) between 50% and 60% in patients treated w

Therapy of acute hepatitis C

✍ Professor Alfredo Alberti; Silvia Boccato; Alessandro Vario; Luisa Benvegnù 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 679 KB

Acute hepatitis C has a high propensity to become chronic, which provides the rationale for treating patients with acute disease attempting to prevent chronicity. Almost all published studies on therapy of acute hepatitis C have been small in size, uncontrolled, and highly heterogeneous as to patien